Kabeer Aziz
InvestorPartner at Adjuvant Capital · Board director at AN2 Therapeutics
New York, New York
Writes $100K – $5M checks · typically $1.5M
Find your path to Kabeer
137 people in our graph share verified history with Kabeer — schools, employers, funds. One of them is your warm intro.
About
Kabeer Aziz is co-founder and partner at Adjuvant Capital. He previously worked at the Global Health Investment Fund, where he managed investments including Themis, Univercells, Atomo Diagnostics, and Access Bio, and earlier held roles at Metalmark Capital investing in healthcare and at Greenhill & Co. advising on biopharmaceutical M&A. He holds a degree from the Stern School of Business at New York University.
Contact· self-published, not guessed
Invests in
BiotechHealthtech
Board director at AN2 Therapeutics
Intro paths
In turn, Kabeer can intro founders to AN2 Therapeutics's investors below.
AN2 Therapeutics's investors · 7
Co-founders at AN2 Therapeutics
Experience
- Adjuvant CapitalPartnercurrent2018 — presentNew York, NY
- AN2 TherapeuticsDirectorcurrent2019 — presentCalifornia, United States
- Minervax ApSDirectorcurrent2020 — presentDenmark
- PulmocideDirectorcurrent2021 — presentUnited Kingdom
- Curevo VaccineBoard Observercurrent2022 — presentWashington, United States
- Frontier Nutrition, Inc.Director2020 — 2026Bangladesh
- ChromaCode, Inc.Director2024 — 2026California, United States
- LimmaTech Biologics AGDirector2023 — 2024Switzerland
- Quantoom BiosciencesDirector2021 — 2023Belgium
- Themis Bioscience GmbHBoard Observer2018 — 2020Austria
- Global Health Investment FundSenior Associate2015 — 2018New York, NY
- Metalmark CapitalAssociate2013 — 2015New York, NY
- Greenhill & Co.Analyst2010 — 2013New York, NY
Investments
Led
Access BioAtomo DiagnosticsThemisUnivercells
Board seats
AN2 TherapeuticsMinervaXUnivercells VaccinesYisheng Biopharma
Sources: the firm's website · curated public sources.
Colleagues at Adjuvant Capital
Network1
Investors connected to Kabeer in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Kabeer Aziz?
- Kabeer Aziz is co-founder and partner at Adjuvant Capital. He previously worked at the Global Health Investment Fund, where he managed investments including Themis, Univercells, Atomo Diagnostics, and Access Bio, and earlier held roles at Metalmark Capital investing in healthcare and at Greenhill & Co. advising on biopharmaceutical M&A. He holds a degree from the Stern School of Business at New York University.
- Where does Kabeer Aziz work?
- Kabeer Aziz is Partner at Adjuvant Capital and Board director at AN2 Therapeutics.
- What does Kabeer Aziz invest in?
- Kabeer Aziz invests in Biotech, Healthtech.
- What check size does Kabeer Aziz write?
- Kabeer Aziz typically writes checks of $100K – $5M.
- What boards does Kabeer Aziz sit on?
- Kabeer Aziz holds tracked board seats at AN2 Therapeutics, MinervaX, Univercells Vaccines, Yisheng Biopharma.
- What companies has Kabeer Aziz invested in?
- Investments tracked here include Access Bio, Atomo Diagnostics, Themis, Univercells, LimmaTech Biologics, MinervaX, Pulmocide.
- Where did Kabeer Aziz go to school?
- Kabeer Aziz studied at NYU Stern School of Business (B.S., Finance & Economics).
- Does Kabeer Aziz lead rounds?
- Yes — Kabeer Aziz has led 4 tracked investments.
Same school
Also attended NYU Stern School of Business810
+ 804 more
